Autres langues TFF Pharmaceuticals, Inc.

Actions

TFFP

US87241J2033

Marché Fermé - Nasdaq Autres places de cotation 22:30:00 09/05/2024			Varia. 5j.	Varia. 1 janv.
2,18 ^USD	+4,31%		-11,74%	-68,95%

30/04	TFF Pharmaceuticals fixe le prix d'une offre publique de 4,8 millions de dollars ; les actions sont en baisse avant la cloche	MT
29/04	TFF Pharmaceuticals, Inc. met à disposition les données de l?essai de phase 2 sur le tacrolimus en poudre pour inhalation pour la prévention du rejet des greffes de poumon, présentées lors de la récente réunion annuelle de l ?	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

TFF Pharmaceuticals Prices $4.8 Million Public Offering; Shares Down Pre-Bell	30/04
TFF Pharmaceuticals Announces Pricing of $4.8 Million Public Offering	30/04
TFF Pharmaceuticals Makes Available Phase 2 Data from Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection Presented at the Recent ISHLT Annual Meeting	29/04
TFF Pharmaceuticals, Inc. Makes Available Phase 2 Data from Tacrolimus Inhalation Powder for Prevention of Lung Transplant Rejection Presented at Recent ISHLT Annual Meeting	29/04
TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessions	16/04
TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessions	15/04
TFF Pharmaceuticals, Inc. Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF Tac) Phase 2 Trial Following Oral Presentation At the Ishlt 44Th Annual Late-Breaking Clinical Science Abstract Sessions	15/04
TFF Pharmaceuticals Files Equities Shelf	08/04
TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results	28/03
Earnings Flash (TFFP) TFF PHARMACEUTICALS Reports Q4 Revenue $114.3M	28/03
TFF Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/03
TFF Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
TFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs	27/03
TFF Pharmaceuticals, Inc. Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (Tff VORI) Clinical Programs	27/03
TFF Pharmaceuticals Announces Oral Presentation of Interim Data from the Phase 2 Study of Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meeting	25/03
TFF Pharmaceuticals Sells Stock in Registered Direct Offering	20/03
TFF Pharmaceuticals Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	20/03
TFF Pharmaceuticals Announces Update on Clinical Programs	20/03
TFF Pharmaceuticals, Inc. Announces Update on Clinical Programs	20/03
TFF Pharmaceuticals to Participate in the 36th Annual Roth Conference – March 17-19, 2024	14/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues TFF Pharmaceuticals, Inc.

Actions

TFFP

US87241J2033

Autres langues

Filtres